RxDoctor Payments Data

Slobodan Miric, MD

Neurology · Englewood, NJNPI 1710908934

Payments from drug & device makers

$36,533in general payments, 2019–2025

Across 705 payments — averaging $51.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$20K
  • Biohaven Pharmaceutical Holding Company Ltd.$7K
  • EMD Serono, Inc.$1K
  • Supernus Pharmaceuticals, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$661
  • Pfizer$650
  • plus $5K from 46 others

What the payments were for

  • Speaking & faculty fees$24,67168%
  • Travel & lodging$9613%
  • Food & beverage$10,88330%
  • Education$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,533 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$189,729
Medicare patients
238
Services billed
1,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5057$737,698
GammakedImmune Globul G/Gly/Iga Avg 4694$704,721
AubagioTeriflunomide13$119,548
Teriflunomide29$72,934
QuliptaAtogepant54$60,624
Nurtec OdtRimegepant Sulfate47$56,421
UbrelvyUbrogepant41$53,011
NourianzIstradefylline15$49,320
NuedextaDextromethorphan Hbr/Quinidine24$39,382
RexultiBrexpiprazole25$35,087
SunosiSolriamfetol Hcl33$30,319
Aimovig AutoinjectorErenumab-Aooe26$25,400
Emgality PenGalcanezumab-Gnlm29$21,932
LamictalLamotrigine12$21,681
XcopriCenobamate11$20,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt$650$794,118104 claims
SanofiAubagio$15$119,54813 claims
AbbVieQulipta, Ubrelvy$20,315$113,63695 claims
Kyowa Kirin, Inc.Nourianz$47$49,32015 claims
Avanir Pharmaceuticals, Inc.Nuedexta$86$39,38224 claims
Otsuka America Pharmaceutical, Inc.Rexulti$17$35,08725 claims
Axsome Therapeutics, Inc.Sunosi$39$30,31933 claims
SK Life Science, Inc.Xcopri$364$20,65911 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$116$15,29440 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 521 neurology providers in New Jersey.

Other neurology in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →